Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced that, following the earlier-than-expected closing of the sale of three skincare brands to L’Oréal and the closing of the divestiture of a manufacturing facility in Brazil, it has reduced its senior secured terms loans by approximately an additional $220 million as of Monday May 1, 2017. In aggregate, the company has now reduced approximately $3.6 billion of debt from the end of first quarter 2016.
The company continues to advance toward its expectation of paying down $5 billion in debt from divestiture proceeds and free cash flow within 18 months of August 2016.
Shares of Valeant closed last Friday at $9.25, down $0.13 or -1.39%. VRX has a 1-year high of $38.50 and a 1-year low of $8.31. The stock’s 50-day moving average is $10.09 and its 200-day moving average is $14.69.
On the ratings front, Valeant has been the subject of a number of recent research reports. In a report issued on April 20, J.P. Morgan analyst Chris Schott reiterated a Hold rating on VRX, with a price target of $10.00, which represents a potential upside of 8% from where the stock is currently trading. Separately, on April 12, Mizuho’s Irina Rivkind Koffler reiterated a Sell rating on the stock and has a price target of $8.00.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Chris Schott and Irina Rivkind Koffler have a yearly average return of 2.2% and 19.6% respectively. Schott has a success rate of 53% and is ranked #1939 out of 4569 analysts, while Koffler has a success rate of 53% and is ranked #105.
Sentiment on the street is mostly neutral on VRX stock. Out of 15 analysts who cover the stock, 9 suggest a Hold rating , 3 suggest a Sell and 3 recommend to Buy the stock. The 12-month average price target assigned to the stock is $14.40, which represents a potential upside of 56% from where the stock is currently trading.
Valeant Pharmaceuticals International, Inc. engages in the development, manufacture, and market of a broad range of pharmaceutical products in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. It operates through the following segments: The Bausch + Lomb/International, The Branded Rx, and The U.S. Diversified products.